About Peptides, Part 2: The Six Peptides Under FDA Compounding Review
Let us discuss the peptides newly reviewed and recommended by the FDA’s compounding committee. These are currently some of the most talked-about unregulated (not FDA-approved as prescription medicines) peptides.
The Pharmacy Compounding Advisory Committee (PCAC) reviewed seven unapproved peptides. Six were recommended for compounding authorization. One was rejected.
None of these peptides have undergone the rigorous clinical trials required for standard FDA drug approval.
The 6 Peptides the Committee Recommended
- BPC-157
- KPV
- TB-500
- MOTS-c
- Semax
- Epitalon
Category 1: Tissue Repair and Cytoprotective Peptides
These peptides are marketed as powerful tools for healing wounds, repairing tendons, and fixing damaged tissue. They show some promise in animal models, but all have minimal or no human studies (studies where humans take these products and the researchers look for effectiveness of the product and also carefully watch for any negative effects coming from taking these compounds).
- BPC-157: Body Protection Compound 157
- TB-500: Thymosin Beta-4
- KPV: Lysine-Proline-Valine
Category 2: Metabolic and Mitochondrial Peptides
These peptides target cellular energy production. MOTS-c is heavily marketed for weight loss and “healthy aging.” But this seems unlikely to be true, since the original research team does not list it as a peptide for FDA trials to get fully approved to sell and make a profit.
- MOTS-c: mitochondrial open reading frame* of the 12S rRNA type-c
*An open reading frame is a section of DNA or RNA that is exposed for production of the encoded protein or RNA molecule. (The exact definition is much more detailed.)
Category 3: Neuropeptides (Brain and Nervous System)
These peptides claim to enhance cognition, improve sleep, or protect the brain. They represent some of the most speculative applications, with the weakest human data of all categories.
- Semax
- Epitalon (Epithalon)
The 6 Peptides Side by Side
This table lets you look at various properties of these 6 peptides.
Scroll the table sideways to see all 11 columns →
| Peptide | What it is | Length | First identified / researched | PCAC* review | Category | Derived from | Potential benefits | Benefits promoted on social media | Risks | Other |
|---|---|---|---|---|---|---|---|---|---|---|
| BPC-157 | Body Protection Compound-157 | 15 AA* | 1991 | Ulcerative colitis | Recovery and performance | Gastric juice | Anti-inflammatory; increased growth of blood vessels; increased fibroblasts (tissue building) | Sports injuries, fast recovery, decreased inflammation, joint pain relief, gut repair, anti-aging, longevity | If there are any cancer cells present in your body, this peptide may increase cancer growth | No oral formulation available; unknown availability when injected. Banned from professional sports |
| KPV | Lysine (K) – Proline (P) – Valine (V) | 3 AA* | 2001 | Wound healing and treating inflammation | Recovery and performance | Melanocyte-stimulating hormone | To treat acne, eczema, gut barrier repair; may decrease inflammation and help with wound healing | Same as potential benefits | Human or other trial studies are limited or do not exist in the USA | None |
| TB-500 | From the natural hormone Thymosin Beta-4 | 43 AA* | 1960 | Not specified | Recovery and performance | Natural hormone Thymosin Beta-4 | Cell proliferation (increasing in number) and migration, for wound healing and tissue recovery from injury | Increased hair growth, decreased inflammation, faster muscle and tendon injury repair, help after workouts | Human or other trial studies are limited or do not exist in the USA | Part of the “Wolverine Stack” on social media. Banned from sports |
| MOTS-c | Mitochondrial Open Reading Frame of the 12S rRNA type-c | 16 AA* | 2015 | Not specified | Longevity | Mitochondria | Cellular stress resistance; aging benefits | Weight loss, increased exercise capacity, metabolism, energy, insulin sensitivity, workout recovery, anti-aging, better body composition | Human or other trial studies are limited or do not exist in the USA | None |
| Semax | Russian-developed peptide | 7 AA* | 1982 | Cerebral ischemia (cell death), migraines, trigeminal neuralgia | Neurological and cognitive | Synthetic, from ACTH (adrenocorticotropic hormone) | Neuroprotective and mood benefits; may decrease amyloid production, helping decrease the rate of dementia | Mental clarity, better focus, decreased brain fog, brain protection, better learning; treats ADHD, decreased anxiety, better mood | Human or other trial studies are limited or do not exist in the USA | Given intranasally. Developed in Russia for stroke recovery and optic nerve atrophy treatment. No American clinical studies yet done |
| Epitalon | Synthetic epithalamin | 4 AA* | 1970 | Insomnia | Neurological | Synthetic epithalamin, a natural peptide from the bovine pineal gland | Telomerase activation (the enzyme that maintains telomeres, the protective ends of chromosomes); anti-aging; sleep and circadian rhythm | Anti-aging, telomere protection, better sleep–wake cycle, sleep and melatonin production; also healthier skin and stronger immunity | Human or other trial studies are limited or do not exist in the USA | None |
*AA = amino acids. *PCAC = the FDA’s Pharmacy Compounding Advisory Committee.
What Is Critical to Understand
A PCAC recommendation for “compounding authorization” is not the same as FDA drug approval.
“It has a substantial body of promising preclinical research, but that has not yet translated into robust clinical evidence in humans.”
Nora Khaldi, PhD, Molecular Scientist
The Standard FDA Drug Approval Process Includes
- Large-scale human clinical trials (Phase 1, 2, and 3)
- Rigorous demonstration of safety and efficacy in human populations
- Manufacturing quality control and Good Manufacturing Practice (GMP) standards
- FDA oversight of prescribing and patient monitoring
- Post-market surveillance and adverse event reporting
What a PCAC Recommendation Allows Compounding Pharmacies to Make and Sell
- State-licensed compounding pharmacies may prepare these substances
- No additional clinical trials
- No FDA premarket review for safety or effectiveness
- No requirement for proof of safety in humans
- Variable quality, purity, and sterility standards
What We Have
- Promising preclinical (animal) data for several compounds
- Small, often uncontrolled human pilot studies for a few compounds
- Extensive marketing and social media promotion
- Growing financial incentives for compounding pharmacies and telehealth clinics
What We Do Not Have
- Large-scale, randomized controlled trials in humans
- Long-term safety data
- Demonstrated superiority over existing treatments
- Understanding of real-world adverse events
If You’re Considering a Peptide, Ask
- Who profits if I buy this? (Selling non-FDA-approved peptides is a billion-dollar business.)
- Am I buying because of hope, or evidence?
- Why did the original discovery lab or pharmaceutical company not develop this drug to sell for the prescription market?
- Am I rushing into buying this because of a great social media post?
The gap between promising animal data and proven human treatments is vast. Just because a peptide shows a signal in mice doesn’t mean it will work safely in you. And just because it’s “compounding authorized” doesn’t mean it’s been proven safe.
Medical disclaimer: This article is for educational purposes only and does not constitute medical advice. All information presented is based on publicly available clinical and regulatory data as of July 2026. Before starting any peptide therapy, consult with a licensed medical provider who can evaluate your individual health status, medication interactions, and risk factors. The FDA regulatory landscape is evolving; always verify current status with up-to-date regulatory resources.